Medical Communications

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …

Samantha O’Shea explains some of the challenges she faces caring for her son, Ethan, who lives with a debilitating but …

A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure …

The saga of Novartis’ ill-advised $1.2 million deal with US President Donald Trump’s lawyer Michael Cohen continues to unfold as …

We are in the midst of a breath-taking series of changes in the world of pharmacovigilance, both within Europe and …

Patient-reported outcomes are becoming increasingly respected and valued by clinical professionals in the pursuit of improving treatment outcomes, but their …

President Trump’s speech on Friday afternoon had been long-anticipated, ever since he was elected and then hammered the pharma industry …

Akari has lost its second CEO in 12 months after David Horn Solomon was accused of misusing the company credit …

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …

AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …

This workshop, through plenary and parallel sessions, will focus on current challenging topics within the global pharmaceutical/biopharmaceutical arena. Attendees from …

C4 Therapeutics has been slowly expanding since its creation in early 2016 out of the prestigious Dana-Farber Cancer Institute. Andrew …